Ondine Biomedical Inc.
OBIMF
$0.25
$0.0847.06%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.03% | 28.33% | 31.01% | 45.31% | 67.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.03% | 28.33% | 31.01% | 45.31% | 67.62% |
| Cost of Revenue | 39.71% | 26.28% | 12.18% | 24.64% | 43.39% |
| Gross Profit | 20.03% | 29.55% | 43.56% | 59.47% | 84.85% |
| SG&A Expenses | -12.40% | 3.13% | 23.53% | 15.67% | 10.56% |
| Depreciation & Amortization | -4.43% | -4.27% | -3.51% | -6.44% | -7.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.22% | 52.21% | 57.45% | 43.46% | 32.04% |
| Operating Income | -51.56% | -54.79% | -60.41% | -43.28% | -29.15% |
| Income Before Tax | -51.96% | -55.90% | -62.49% | -44.89% | -30.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.96% | -55.90% | -62.49% | -44.89% | -30.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.96% | -55.90% | -62.49% | -44.89% | -30.31% |
| EBIT | -51.56% | -54.79% | -60.41% | -43.28% | -29.15% |
| EBITDA | -50.80% | -53.96% | -59.69% | -43.19% | -29.64% |
| EPS Basic | 10.14% | 6.11% | 1.46% | 5.47% | 7.37% |
| Normalized Basic EPS | 9.87% | 7.10% | 3.61% | 7.65% | 9.25% |
| EPS Diluted | 10.14% | 6.11% | 1.46% | 5.47% | 7.37% |
| Normalized Diluted EPS | 9.87% | 7.10% | 3.61% | 7.65% | 9.25% |
| Average Basic Shares Outstanding | 69.37% | 69.18% | 68.94% | 54.95% | 39.31% |
| Average Diluted Shares Outstanding | 69.37% | 69.18% | 68.94% | 54.95% | 39.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |